RxDoctor Payments Data

Kristin Viola, PA

Physician Assistant · Orange, CANPI 1619517778

Payments from drug & device makers

$14,183in general payments, 2019–2025

Across 733 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novartis$1K
  • Amgen$840
  • Bristol Myers Squibb$801
  • Merck$728
  • Seagen Inc.$650
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$13,90498%
  • Education$2802%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)59$1,176
Novartis53$1,051
Amgen40$840
Bristol Myers Squibb51$801
Merck33$728
Seagen Inc.37$650
Incyte Corporation30$564
Pfizer35$557
E.r. Squibb & Sons, L.L.C.46$519
Pharmacyclics LLC, An Abbvie Company31$503
Eisai Inc.22$498
AbbVie19$418
Daiichi Sankyo Inc.23$410
Exelixis Inc.12$397
Takeda Pharmaceuticals U.S.A., Inc.17$384
Myovant Sciences Inc.20$326
Johnson & Johnson12$274
Bayer14$248
Boehringer Ingelheim11$232
Beigene USA, Inc.9$224
Astellas Pharma US Inc8$222
Stemline Therapeutics Inc.12$214
Pharmaessentia USA Corporation6$205
Puma Biotechnology, Inc.7$177
Coherus Oncology, Inc.9$164
Morphosys, US Inc.8$158
Blueprint Medicines Corporation6$157
Genentech USA, Inc.6$151
Karyopharm Therapeutics Inc.7$148
GSK8$134
Regeneron Healthcare Solutions, Inc.4$112
Lilly USA, LLC5$105
Sanofi6$98
AVEO Pharmaceuticals, Inc.5$98
Sumitomo Pharma America, Inc.5$95
Gilead4$93
Taiho Oncology, Inc.5$88
Genmab U.S., Inc.3$77
CSL Behring5$76
Ipsen Biopharmaceuticals, Inc4$72
GE HealthCare2$70
Kyowa Kirin, Inc.3$69
Pharmacosmos Therapeutics Inc.3$64
Rigel Pharmaceuticals, Inc.3$63
Alnylam Pharmaceuticals Inc.3$61
Sobi, Inc3$47
Agios Pharmaceuticals, Inc.2$44
Deciphera Pharmaceuticals Inc.2$43
Servier Pharmaceuticals LLC2$38
EMD Serono, Inc.2$38
AMAG Pharmaceuticals, Inc.1$30
EUSA Pharma (US) LLC2$27
Accord Healthcare, Inc.1$25
Mylan Institutional Inc.1$25
Dendreon Pharmaceuticals LLC1$21
Recordati_rare_diseases_inc.1$21
Mirati Therapeutics, Inc.1$20
ADC Therapeutics America, Inc.1$14
CTI Biopharma Corp.1$12
Global Blood Therapeutics, Inc.1$12

How this compares

$14,183 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$6,227
Medicare patients
28
Services billed
61

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib39$621,355
RevlimidLenalidomide20$394,798
XtandiEnzalutamide19$273,223
JakafiRuxolitinib Phosphate19$246,752
EliquisApixaban68$98,801
DopteletAvatrombopag Maleate11$96,071
Imatinib Mesylate12$15,767
Exemestane17$2,653
Anastrozole84$2,070
Letrozole82$1,874
Hydroxyurea16$502
Acyclovir26$255
Warfarin Sodium19$234
Ondansetron OdtOndansetron12$220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$557$720,156107 claims
Bristol Myers SquibbRevlimid$801$394,79820 claims
Astellas Pharma US IncXtandi$222$273,22319 claims
Incyte CorporationJakafi$564$246,75219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →